Drug intelligence / Profile preview

IA-201

Development stage: Preclinical
Lead developer: ImmuneAGE Bio
Modality: Small Molecules
Administration: Parenteral

Overview

IA-201 is an ex vivo immune rejuvenation cocktail developed by ImmuneAGE Bio. It is designed to target hematopoietic stem cells (HSCs) in the bone marrow to facilitate chemotherapy recovery and improve outcomes in bone marrow transplantation. The drug is part of a platform that utilizes large-scale combinatorial drug screening to identify geroprotective cocktails capable of rejuvenating the immune system. IA-201 specifically focuses on the ex vivo treatment or expansion of HSCs to restore immune function in patients undergoing intensive treatments that deplete the bone marrow.

Beyond the preview

Go deeper on IA-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IA-201.

Explore the full profile